Wall Street Zen Upgrades Burning Rock Biotech (NASDAQ:BNR) to Buy

Burning Rock Biotech (NASDAQ:BNR) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Burning Rock Biotech Stock Performance

Shares of BNR stock opened at $21.70 on Friday. The company has a current ratio of 3.14, a quick ratio of 2.91 and a debt-to-equity ratio of 0.03. Burning Rock Biotech has a 12 month low of $2.18 and a 12 month high of $23.59. The company’s fifty day moving average price is $14.70 and its 200-day moving average price is $9.37. The stock has a market cap of $233.49 million, a PE ratio of -13.07 and a beta of 1.20.

Institutional Investors Weigh In On Burning Rock Biotech

Several institutional investors have recently bought and sold shares of BNR. Crcm LP raised its holdings in shares of Burning Rock Biotech by 13.8% during the third quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after acquiring an additional 26,809 shares during the last quarter. Prospera Financial Services Inc purchased a new stake in shares of Burning Rock Biotech during the third quarter worth approximately $214,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Burning Rock Biotech in the 3rd quarter valued at $26,000. 30.03% of the stock is currently owned by institutional investors and hedge funds.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.